SWOG clinical trial number
S9713

A Phase II Trial of Cisplatin/Etoposide and Concurrent, Radiotherapy Followed by Paclitaxel/Carboplatin Consolidation For Limited Stage Small Cell Lung Cancer

Closed
Phase
Accrual
100%
Published
Abbreviated Title
CDDP+VP-16+RT -> Taxol/Carbo in SCLC
Activated
07/01/1998
Closed
08/01/1999

Research committees

Lung Cancer

Publication Information Expand/Collapse

2004

Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713

MJ Edelman;K Chansky;LE Gaspar;B Leigh;GR Weiss;SA Taylor;J Crowley;R Livingston;DR Gandara Journal of Clinical Oncology 22(1):127-132

2002

Phase II (SWOG 9713) trial of cisplatin/etoposide (PE) and concurrent radiotherapy (XRT) followed by paclitaxel/carboplatin (TC) consolidation for limited small cell lung cancer (LSCLC)

MJ Edelman;K Chansky;B Leigh;J Crowley;DR Gandara Proc of the American Society of Clinical Oncology 21:303a(#1210)

Other Clinical Trials

SWOG Clinical Trial Number
A082302

EVALUATING ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS TO PREVENT RECURRENCE IN STAGE I NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL (AASI-NSCLC)
Research Committee(s)
Lung Cancer
Activated
03/02/2027
Open
SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase